Delving into the Latest Updates on Ciprofol with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Cipepofol, cipepofol, 环丙酚

+ [2]

Target

GABAA receptor

Action

agonists

Mechanism

GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)

Therapeutic Areas

Other Diseases

Active Indication

SedationAnesthesia

Inactive Indication

Chronic liver disease

Originator Organization

Haisco Pharmaceutical Group Co., Ltd.

Active Organization

Shenyang Haisike Pharmaceutical Co., Ltd.

Haisco Pharmaceutical Group Co., Ltd.Haisco Usa Pharmaceuticals, Inc.

Inactive Organization

Liaoning Haisco Pharmaceutical Co., Ltd.

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (11 Dec 2020),

Sedation

RegulationSpecial Review Project (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC14H20O

InChIKeyBMEARIQHWSVDBS-SNVBAGLBSA-N

CAS Registry1637741-58-2

Post-procedural fatigue is common after sedated gastrointestinal endoscopy and prolongs recovery. We describe a protocol for a prospective, single-center, randomized, controlled, 3 × 3 factorial trial to evaluate the effects of different sedative-analgesic combinations on patient-reported fatigue after gastrointestinal endoscopy.

PATIENTS AND METHODS:

Three hundred and fifteen patients (aged ≥ 45 years, ASA physical status I or II) presenting for gastrointestinal endoscopy with planned intravenous sedation will be randomly allocated (1:1:1:1:1:1:1:1:1; block sizes 9 and 18) to one of nine equip-sized groups generated by the factorial combination of three sedatives (propofol, ciprofol, remimazolam) with three adjuvant analgesics (sufentanil, esketamine, lidocaine). Sedation will be titrated to Modified Observer's Assessment of Alertness/Sedation scores of 1-2. The primary outcome is the Christensen Fatigue Scale score (range 1-10; higher = worse) 30 min after the procedure. The secondary outcome is the composite incidence of intra-procedural hypotension (mean arterial pressure < 65 mmHg) and hypoxemia (SpO₂ < 90% for ≥ 10 s). Primary analysis will employ two-way factorial ANOVA to test the main effects of sedatives and analgesics on the 30-min fatigue score, with an exploratory interaction analysis.

DISCUSSION:

The results of this trial will provide high-resolution evidence on which sedative or analgesic agent most effectively mitigates early post-endoscopy fatigue, thereby informing patient-centered sedation choices and enhancing recovery.

TRIAL REGISTRATION:

Chinese Clinical Trial Registry (ChiCTR2500112657; registered on November 18, 2025).

01 Apr 2026·Anaesthesia Critical Care & Pain Medicine

Jiancheng dual-channel vs. i-gel laryngeal mask airway for fiberoptic bronchoscopy: A randomized trial

Article

Author: Dai, Ru-Ping ; Zhou, Pei ; Hu, Zhao-Lan ; Luo, Ru-Yi ; Huang, Yun-Xuan ; Wang, Wen ; Luo, Wei ; Luo, Cong

BACKGROUND:

Fiberoptic bronchoscopy (FB) procedures have become increasingly lengthy and complex. Maintaining deep sedation while preventing hypoxemia with conventional oropharyngeal/nasopharyngeal airways presents a significant clinical challenge. Supraglottic airway devices, such as the laryngeal mask airway (LMA), may provide improved oxygenation and procedural efficiency during FB. However, despite the variety of LMA designs, no previous studies have definitively established the optimal type of LMA for FB procedures.

METHODS:

96 patients were randomized to either the i-gel LMA group (group I) or Jiancheng dual-channel LMA group (group J). Remimazolam besylate, ciprofol, and sufentanil were used for anesthesia induction and maintenance in both groups. We measured and recorded the success rate of LMA insertion and entering the main airway through the LMA at first attempt, operational interference, mid-procedure LMA adjustments, procedure interruptions, vital signs, and major adverse events.

RESULTS:

The patients in group J experienced higher success rates of first-attempt LMA insertion (P < 0.01) and entry into the main airway (P < 0.01) than those in group I. The incidence of coughing was significantly higher in group I than in group J (P < 0.01). The incidence of cardiopulmonary adverse reactions, including respiratory arrest, airway obstruction, airway spasm, laryngospasm, hypertension, and hypotension, was comparable between the two groups. Group I demonstrated a tendency toward prolonged recovery time compared with group J (P = 0.05).

CONCLUSIONS:

The Jiancheng dual-channel LMA is associated with higher first-attempt success for airway insertion and bronchoscopy compared to the i-gel LMA, warranting consideration for broader clinical application.

TRIAL REGISTRATION:

https://www.chictr.org.cn/showproj.html?proj=265357 (registration no. ChiCTR2500100990, principal investigator: Ru-Ping Dai, date of registration: April 17, 2025).

04 Mar 2026·Expert Opinion On Drug Safety

Comparison of ciprofol and propofol on dreaming and emotional response during painless gastroscopy: a single-center randomized controlled trial

Article

Author: Feng, Xinyi ; Li, Kunjie ; Zhong, Tao ; Wu, Jiahao ; Xiong, Luran ; Yang, Yong

BACKGROUND AND AIMS:

Ciprofol (HSK3486), a novel intravenous anesthetic with a chemical structure similar to propofol, is not inferior to propofol in terms of its effectiveness. We compared the effects of ciprofol and propofol on dreams and emotional states in patients following painless gastroscopy.

RESEARCH DESIGN AND METHODS:

This was a single-center, randomized controlled trial. The primary outcome was the proportion of positive dreams during sedation.

RESULTS:

A total of 110 outpatients were included, with 55 in each group. The proportion of positive dreams among dreamers was significantly greater in the propofol group than in the ciprofol group (60.9% vs 20.0%; p = 0.020). Additionally, the propofol group exhibited significantly higher positive emotion scores compared to the ciprofol group (19 [15,25] vs 17 [12,21]; p = 0.021). No significant differences were observed in vital signs, BIS values, or satisfaction with the procedure between the two groups. As for the adverse drug reactions, the incidence of injection pain of propofol was significantly higher than that of ciprofol (12.7% vs 0%; p = 0.013).

CONCLUSIONS:

Compared to propofol, ciprofol demonstrated a weaker capacity to induce positive dreams and emotions during painless gastroscopy. However, this does not impact patient satisfaction with the procedure.

CLINICAL TRIAL REGISTRATION:

www.chictr.org.cn; identifier: ChiCTR2400082655.

100 Deals associated with Ciprofol

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	N05C	DB16295

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Sedation	China	Shenyang Haisike Pharmaceutical Co., Ltd.	11 Dec 2020

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anesthesia	NDA/BLA	China	Liaoning Haisco Pharmaceutical Co., Ltd.	02 Aug 2019
Chronic liver disease	Phase 1	China	Haisco Pharmaceutical Group Co., Ltd.	07 Nov 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05518929 (Pubmed \| Dig Endosc)	Phase 4	Hypoxia	1,018	Ciprofol	yxkvrwibcb(qcudvasvhp) = bcsnmghnrz jtukyymome (qkhjkqhtde ) View more	Positive	01 Feb 2026
				Propofol	yxkvrwibcb(qcudvasvhp) = gnsgjztwcz jtukyymome (qkhjkqhtde ) View more
NCT06795204 (CTgov)	Phase 1	Arrhythmias, Cardiac	48	HSK3486 (HSK3486( Study Drug))	xpwxftaubu(iqtjipsegr) = qiqjkaxppj zxuvwftzhg (zbwuiueddm, eoaufxcaqp - fjeiadvtll) View more	-	13 Jan 2026
				Placebo (Placebo)	xpwxftaubu(iqtjipsegr) = lcubfnuiba zxuvwftzhg (zbwuiueddm, xocxavxgpm - fxdijfadhz) View more
NCT06172140 (Pubmed \| Ann Med)	Not Applicable	-	124	Ciprofol	fdchubgnnz(bkyugamnzx) = niqgogpkny mijrgsdfal (fkihnlcytu ) View more	Positive	31 Dec 2025
				Propofol	fdchubgnnz(bkyugamnzx) = fkglvhtjve mijrgsdfal (fkihnlcytu ) View more
NCT05486416 (CTgov)	Phase 3	Anesthesia	465	HSK3486 (HSK3486 for General Anesthesia Induction)	rkhaxuuvou = ogidwarhog igajbeoguf (svlnqkpgcz, qbsofytwro - wrecwatchc) View more	-	11 Aug 2025
				Propofol (Propofol for General Anesthesia Induction)	rkhaxuuvou = xtzvavgvet igajbeoguf (svlnqkpgcz, ddqtngozgz - xjfmcnqasx) View more
NCT05522998 (Pubmed \| PLoS One)	Phase 4	Obesity	212	Ciprofol 0.5 mg/kg	xjseqjmkpn(vjqgnxregt) = wzhfufznbe saufarlfrl (zjpwtmxzsi ) View more	Positive	24 Jul 2025
				Propofol 2.5 mg/kg	xjseqjmkpn(vjqgnxregt) = alfwylbcga saufarlfrl (zjpwtmxzsi ) View more
NCT06287138 (Pubmed \| Front Med (Lausanne))	Not Applicable	-	20	Cipepofol	fnqhnojqmn(mrmxcluriv) = reductions in P0.1 (p = 0.020) were significant zkraojigky (noeesjpqqt ) View more	Positive	25 Feb 2025
ChiCTR2100047580 (Pubmed \| BMC Anesthesiol)	Phase 1	Gastrointestinal Neoplasms	30	Ciprofol	pdzkbhffqx(lakuwcljxq) = nqxopflkcw jsvpapjmfy (ytqhufkzem, 900.0) View more	Positive	27 Jan 2025
				Propofol	diinjvjfca(ybjrxwfeso) = lyqwgdgknq hobkgxpexm (mcvcycazwg ) View more
NCT06413862 (Pubmed \| BMC Anesthesiol)	Not Applicable	-	217	Ciprofol combined with alfentanil	wihcdrrkib(fopszpqqgj) = xeivmjmdrv lfnhiegmtv (wvypvcmsmj ) View more	Positive	12 Nov 2024
				Propofol combined with alfentanil	wihcdrrkib(fopszpqqgj) = zqqqesdntw lfnhiegmtv (wvypvcmsmj ) View more
NCT05478174 (CTgov)	Phase 3	Anesthesia	400	HSK3486 (HSK3486)	jgfqfpsqai = wlhzxkqxwr ppebvcqhjx (bsiwinngbz, dmbbifzzjf - imwylbcmcn) View more	-	29 Oct 2024
				Propofol (Propofol)	jgfqfpsqai = nugbvhygde ppebvcqhjx (bsiwinngbz, jsbhxatxmf - esrqpsrzuu) View more
NCT04147416 \| NCT04620031 (phase 2 and phase 3 trials, Pubmed \| Ann Intensive Care)	Phase 2/3	-	174	Ciprofol	hueqldfazh(jqxpltiwjw) = gitoxskmjg umwqeqqlwq (xortnlvkla )	Positive	26 Oct 2024
				Propofol	hueqldfazh(jqxpltiwjw) = lwzqateeir umwqeqqlwq (xortnlvkla )